Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06076-1 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Cécile Tomowiak und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department and CIC1402 INSERM, University Hospital, Poitiers, France. cecile.tomowiak@chu-poitiers.fr. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Purines, Quinazolinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We present the 6-year update of a phase 2 study evaluating the combination of obinutuzumab and idelalisib in relapse/refractory Waldenstrom macroglobulinemia. The results of the REMODEL trial demonstrated interesting efficacy in a high-risk genotype profile population. The primary endpoint was achieved with a median PFS of 25.4 months (95% CI, 15.7 to 29.0). However, a major limitation of idelalisib is its toxicity. With a median follow-up of 70.9 months, median OS was still not reached, and 5-year OS was 72.9% (95% CI, 61.3 to 86.6). We confirm that CXCR4 mutations had no impact on PFS or OS. However, TP53 mutated patients had shorter OS. At the time of analysis, six patients are alive without relapse and 40 had progressive disease. Among the 38 patients who received a new treatment, the median time to second progression was not reached in ibrutinib treated patients (n = 17) versus 30.8 months in patients treated with other options (95% CI, 16.9 to NA), p = 0.005. With longer follow-up our prospective study is the first to show an impact of TP53 mutations in patients treated with fixed duration chemo-free regimen leading to a significant shorter OS in this population. Moreover, ibrutinib remains an effective treatment after this combination. This study was registered on the clinicaltrial.gov web (NCT02962401, November 9, 2016).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department and CIC1402 INSERM, University Hospital, Poitiers, France. cecile.tomowiak@chu-poitiers.fr.
- Service d'Hématologie Et Thérapie Cellulaire, PRC, Hôpital de La Milétrie, Faculté de Médecine And Inserm CIC 1402, CHU, 2 Rue de La Milétrie, 86021, Poitiers Cedex, France. cecile.tomowiak@chu-poitiers.fr.
- INSERM 1277-CNRS 9020 UMRS 12, University of Lille, Lille, France.
- Laboratory of Hematology, Biology and Pathology Center, CHU de Lille, F-59000, Lille, France.
- Department of Blood Diseases, University Hospital, Lille, France.
- Hematology Department, University Hospital, Vandoeuvre-Les-Nancy, France.
Zitieren
APA
Tomowiak, C., Poulain, S., Nudel, M., Feugier, P., Herbaux, C., Mahé, B., Morel, P., Aurran, T., Tournilhac, O., Leprêtre, S., Assaad, S., Villemagne, B., Casasnovas, O., Lhermitte, A., Roos-Weil, D., Torregrosa-Diaz, J., Chevret, S., Leblond, V., & on the behalf of the FILO group (2024). Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-06076-1
Vancouver
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, et al. Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-06076-1
BibTeX
@article{Tomowiak2024,
author = {Tomowiak, Cécile and Poulain, Stéphanie and Nudel, Morgane and Feugier, Pierre and Herbaux, Charles and Mahé, Béatrice and Morel, Pierre and Aurran, Thérèse and Tournilhac, Olivier and Leprêtre, Stéphane and Assaad, Souad and Villemagne, Bruno and Casasnovas, Olivier and Lhermitte, Adeline and Roos-Weil, Damien and Torregrosa-Diaz, José and Chevret, Sylvie and Leblond, Véronique and on the behalf of the FILO group, on the behalf of the FILO group},
title = {Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06076-1}
}
EUVIMED